DKB-119

DKB-119 is an injectable investigational drug developed by Dongkook Pharmaceutical principally studied for the treatment of **crow’s feet (lateral canthal lines)**, a type of facial wrinkle[1][2][3][4][5]. The main clinical development involves a randomized, blinded, split-face pivotal trial assessing its efficacy and safety for the non-inferiority to active or control interventions in adults aged 19–70 with moderate or greater crow's feet[2]. The specific molecular composition, pharmacological class, and mechanism of action of DKB-119 are not disclosed in public sources. It is administered via injection, indicating a likely local dermatological modality, but the route (e.g., subcutaneous vs. intradermal) is not specified. No details on the active ingredient, target(s), or modality (such as peptide, toxin, biologic, or small molecule) are currently available.

Brand names

DKB-119DKB119DKB 119

Other names

DKB-119DKB119DKB 119